JP2011512347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011512347A5 JP2011512347A5 JP2010546398A JP2010546398A JP2011512347A5 JP 2011512347 A5 JP2011512347 A5 JP 2011512347A5 JP 2010546398 A JP2010546398 A JP 2010546398A JP 2010546398 A JP2010546398 A JP 2010546398A JP 2011512347 A5 JP2011512347 A5 JP 2011512347A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- iminosugar
- composition according
- sugar
- imino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims 30
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- SEWARTPIJFHCRP-UHFFFAOYSA-N N-hydroxypipecolic acid Chemical compound ON1CCCCC1C(O)=O SEWARTPIJFHCRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 claims 1
- 208000013824 Acidemia Diseases 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- HAJKHJOABGFIGP-UHFFFAOYSA-N indolizidine Chemical compound C1CCCN2CCCC21 HAJKHJOABGFIGP-UHFFFAOYSA-N 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- ADRDEXBBJTUCND-UHFFFAOYSA-N pyrrolizidine Chemical compound C1CCN2CCCC21 ADRDEXBBJTUCND-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 OC(CNC(*C(O)=O)C1O)C1O Chemical compound OC(CNC(*C(O)=O)C1O)C1O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0802903.5 | 2008-02-18 | ||
| GB0802907.6 | 2008-02-18 | ||
| GB0802904A GB0802904D0 (en) | 2008-02-18 | 2008-02-18 | Treatment of metabolic syndrome |
| GB0802903A GB0802903D0 (en) | 2008-02-18 | 2008-02-18 | Treatment of diabetes |
| GB0802907A GB0802907D0 (en) | 2008-02-18 | 2008-02-18 | Method for monitoring the quality of a herbal food additive |
| GB0802904.3 | 2008-02-18 | ||
| PCT/GB2009/000417 WO2009103953A1 (en) | 2008-02-18 | 2009-02-17 | Treatment of energy utilization disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011512347A JP2011512347A (ja) | 2011-04-21 |
| JP2011512347A5 true JP2011512347A5 (enExample) | 2013-04-11 |
| JP5722632B2 JP5722632B2 (ja) | 2015-05-27 |
Family
ID=40589554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546398A Active JP5722632B2 (ja) | 2008-02-18 | 2009-02-17 | エネルギー利用疾病の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20110015226A1 (enExample) |
| EP (1) | EP2257286B1 (enExample) |
| JP (1) | JP5722632B2 (enExample) |
| CN (1) | CN102006869B (enExample) |
| CA (1) | CA2752868C (enExample) |
| ES (1) | ES2620743T3 (enExample) |
| WO (1) | WO2009103953A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10273598B2 (en) | 2009-12-22 | 2019-04-30 | Element Six Technologies Limited | Synthetic CVD diamond |
| KR101598935B1 (ko) * | 2010-04-16 | 2016-03-03 | 씨제이제일제당(주) | 레바우디오사이드 ａ의 생산 공정에서 발생하는 부산물을 재활용하여 고수득율의 레바우디오사이드 ａ를 제조하는 방법 |
| GB201117490D0 (en) * | 2011-10-11 | 2011-11-23 | Phytoquest Ltd | Anti-inflammatory compounds |
| GB2496388B (en) * | 2011-11-08 | 2014-10-08 | Phynova Ltd | Morus extracts rich in n-acids of imino sugars and or pipecolic acids |
| GB201313440D0 (en) | 2013-07-29 | 2013-09-11 | Phytoquest Ltd | Characterization of rice |
| JP6283569B2 (ja) * | 2014-05-26 | 2018-02-21 | 株式会社シャローム | 脂肪蓄積抑制物質の製造方法 |
| CN105624181B (zh) * | 2014-11-03 | 2019-06-11 | 中国科学院微生物研究所 | 一种高通量鉴定产生1-脱氧野尻霉素菌株的方法 |
| KR102408480B1 (ko) * | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
| CN119950503A (zh) * | 2019-07-26 | 2025-05-09 | 植物探索有限公司 | 生物活性植物化学物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| WO1992021657A1 (en) | 1991-05-30 | 1992-12-10 | The Scripps Research Institute | Omega-deoxy-azasugars |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| WO2000056334A1 (en) * | 1999-03-19 | 2000-09-28 | The Trustees Of Boston College | Use of imino sugars for anti-tumor therapy |
| WO2000066105A2 (en) * | 1999-04-30 | 2000-11-09 | The Trustees Of Boston College | Treatment of epilepsy with imino sugars |
| US20040019082A1 (en) * | 2002-03-13 | 2004-01-29 | United Therapeutics Corporation | Reversible infertility in male mice following oral administration of alkylated imino sugars: a non-hormonal approach to male contraception |
| US20060025449A1 (en) | 2004-03-25 | 2006-02-02 | United Therapeutics | Use of N-substituted imino sugars for appetite suppression |
| JP2007262017A (ja) | 2006-03-29 | 2007-10-11 | Ajinomoto Co Inc | ピペコリン酸含有抗糖尿病組成物 |
-
2009
- 2009-02-17 JP JP2010546398A patent/JP5722632B2/ja active Active
- 2009-02-17 CA CA2752868A patent/CA2752868C/en active Active
- 2009-02-17 US US12/918,037 patent/US20110015226A1/en not_active Abandoned
- 2009-02-17 WO PCT/GB2009/000417 patent/WO2009103953A1/en not_active Ceased
- 2009-02-17 CN CN2009801136557A patent/CN102006869B/zh active Active
- 2009-02-17 ES ES09712052.1T patent/ES2620743T3/es active Active
- 2009-02-17 EP EP09712052.1A patent/EP2257286B1/en active Active
-
2013
- 2013-02-05 US US13/759,173 patent/US20140011841A1/en not_active Abandoned
-
2015
- 2015-12-18 US US14/974,536 patent/US10842784B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512347A5 (enExample) | ||
| JP4643760B2 (ja) | Ｄｐｐ−ｉｖ阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| JP2015512949A5 (enExample) | ||
| JP2008007519A5 (enExample) | ||
| JP2006348039A5 (enExample) | ||
| AR036584A1 (es) | Combinaciones | |
| TW200738246A (en) | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | |
| JP2010525084A5 (enExample) | ||
| JP2014516700A5 (enExample) | ||
| JP2007530577A5 (enExample) | ||
| JP2014516701A5 (enExample) | ||
| JP2006514611A5 (enExample) | ||
| TW200815384A (en) | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein | |
| US20200054633A1 (en) | Combination therapies for treating influenza virus infection | |
| JP2021530510A (ja) | 心臓に安全な抗糖尿病療法 | |
| US20140128402A1 (en) | Pharmaceutical combination | |
| JP2008531558A5 (enExample) | ||
| Béïque et al. | Interactions between protease inhibitors and acid‐reducing agents: a systematic review | |
| JP2009517411A5 (enExample) | ||
| JP2018527374A5 (enExample) | ||
| WO2018100557A1 (en) | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease | |
| KR20190044666A (ko) | Fxr 작용제들의 조합물 | |
| Mahler et al. | Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3) | |
| JP2014531949A5 (enExample) | ||
| JP2008031164A5 (enExample) |